ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 333,36
0,79%
Dow Jones
40 008,39
0,61%
DAX
17 885,60
0,45%
Brent Oil
79,55
-0,09%
Bitcoin
58 910,85
0,34%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
14/08/202413h06Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NYSE:TEVATeva Pharmaceutical Industries Ltd
13/08/202422h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
09/08/202421h59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
31/07/202422h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:TEVATeva Pharmaceutical Industries Ltd
31/07/202413h00Edgar (US Regulatory)Form 8-K - Current reportNYSE:TEVATeva Pharmaceutical Industries Ltd
31/07/202413h00GlobeNewswire Inc.Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial GuidanceNYSE:TEVATeva Pharmaceutical Industries Ltd
31/07/202412h01IH Market NewsUS Index Futures Up Ahead of Fed Decision; Oil Prices Surge Amid Middle East TensionsNYSE:TEVATeva Pharmaceutical Industries Ltd
25/07/202407h30Business WireTeva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel DiseaseNYSE:TEVATeva Pharmaceutical Industries Ltd
18/07/202414h30Business WireTeva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic MigraineNYSE:TEVATeva Pharmaceutical Industries Ltd
03/07/202400h00Business WireTeva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
29/06/202400h34Business WireLes nouvelles données portant sur AJOVY® (fremanezumab) dans la prévention de la migraine remettent en question les pauses thérapeutiquesNYSE:TEVATeva Pharmaceutical Industries Ltd
28/06/202421h41Business WireNeue Daten zu AJOVY® (Fremanezumab) zur Migräneprävention stellen Behandlungspausen in FrageNYSE:TEVATeva Pharmaceutical Industries Ltd
28/06/202417h30Business WireNew AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment PausesNYSE:TEVATeva Pharmaceutical Industries Ltd
25/06/202414h00Business WireTeva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020NYSE:TEVATeva Pharmaceutical Industries Ltd
24/06/202415h50Business WireTeva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
14/06/202413h21IH Market NewsAdobe Soars 15% Pre-Market; Visa and Mastercard Encounter Hurdles in $30 Billion Agreement, and MoreNYSE:TEVATeva Pharmaceutical Industries Ltd
04/06/202422h05Business WireTeva to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
01/06/202420h25Business WireNew Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)NYSE:TEVATeva Pharmaceutical Industries Ltd
01/06/202420h20Business WireTeva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
30/05/202400h38Business WireTeva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)NYSE:TEVATeva Pharmaceutical Industries Ltd
21/05/202402h25GlobeNewswire Inc.Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
15/05/202414h15Business WireTeva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global OperationsNYSE:TEVATeva Pharmaceutical Industries Ltd
09/05/202413h53IH Market NewsBain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More NewsNYSE:TEVATeva Pharmaceutical Industries Ltd
08/05/202413h00Business WireTeva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial OutlookNYSE:TEVATeva Pharmaceutical Industries Ltd
08/05/202412h30Business WireTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with SchizophreniaNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/202400h30Business WireTeva to Present at the 2024 Bank of America Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
02/05/202414h30Business WireTeva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious TargetsNYSE:TEVATeva Pharmaceutical Industries Ltd
30/04/202410h00GlobeNewswire Inc.U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
16/04/202423h43Business WireAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
16/04/202414h00Business WireTeva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) TabletsNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

COIN
BTCUSD
Bitcoin
EU
AF
Air FranceKLM
COIN
DOGEUSD
Dogecoin
EU
CS
Axa
NASDAQ
MSFT
Microsoft
EU
ML
Michelin
EU
BN
Danone
COIN
XRPUSD
Ripple
EU
VK
Vallourec
SPI
SP500
S&P 500
EU
MC
Lvmh Moet Hennessy Louis...
EU
BEL20
Bel 20
NYSE
NKE
Nike
EU
HO
Thales
EU
VIV
Vivendi
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés